Teva Pharmaceutical Industries (NYSE:TEVA) released its quarterly earnings data on Thursday. The company reported $0.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.14, Morningstar.com reports. Teva Pharmaceutical Industries had a positive return on equity of 14.52% and a negative net margin of 72.66%. The business had revenue of $5.46 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the previous year, the firm posted $1.38 EPS. The business’s revenue for the quarter was down 15.9% compared to the same quarter last year. Teva Pharmaceutical Industries updated its FY18 guidance to $2.25-2.50 EPS.

Shares of Teva Pharmaceutical Industries (NYSE TEVA) opened at $18.61 on Friday. Teva Pharmaceutical Industries has a 12 month low of $10.85 and a 12 month high of $37.94. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20. The company has a market capitalization of $19,300.00, a price-to-earnings ratio of -1.15, a PEG ratio of 1.35 and a beta of 0.59.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Bank of Nova Scotia raised its position in shares of Teva Pharmaceutical Industries by 8.3% during the second quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock worth $229,000 after purchasing an additional 528 shares during the period. Caxton Associates LP raised its position in shares of Teva Pharmaceutical Industries by 6.6% during the second quarter. Caxton Associates LP now owns 13,000 shares of the company’s stock worth $432,000 after purchasing an additional 800 shares during the period. Oak Associates Ltd. OH raised its position in shares of Teva Pharmaceutical Industries by 0.6% during the second quarter. Oak Associates Ltd. OH now owns 379,924 shares of the company’s stock worth $12,621,000 after purchasing an additional 2,114 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Teva Pharmaceutical Industries by 1.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 198,178 shares of the company’s stock worth $3,755,000 after purchasing an additional 3,100 shares during the period. Finally, WealthTrust Axiom LLC raised its position in shares of Teva Pharmaceutical Industries by 29.9% during the fourth quarter. WealthTrust Axiom LLC now owns 14,948 shares of the company’s stock worth $283,000 after purchasing an additional 3,440 shares during the period. 51.99% of the stock is currently owned by institutional investors.

A number of research analysts have issued reports on the company. Goldman Sachs Group upgraded Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $20.00 price target for the company in a research report on Friday, December 15th. Credit Suisse Group reiterated an “underperform” rating and set a $8.00 price target (down previously from $14.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, November 6th. Cantor Fitzgerald set a $18.00 price target on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Thursday, December 28th. Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Sunday, November 12th. Finally, BTIG Research set a $16.00 price target on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research report on Tuesday, November 28th. Ten research analysts have rated the stock with a sell rating, seventeen have given a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $21.15.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://theolympiareport.com/2018/02/10/teva-pharmaceutical-industries-teva-issues-earnings-results-beats-estimates-by-0-14-eps.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Earnings History for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.